ライフサイエンスコーパス: MSA

1 MSA has been divided into two clinicopathological subtyp

2 MSA is a slowly evolving disorder characterized by progr

3 MSA results in significant manometric improvement of the

4 MSA was associated with an overall increase in the media

5 Brain extracts from 14 MSA cases all transmitted neurodegeneration to TgM83(+/-

6 active in all CON, and positive in all but 2 MSA cases.

7 In this first release, R3D-2-MSA provides manual and programmatic access to curated,

8 The R3D-2-MSA server maps these ranges to the appropriate columns

9 to-Multiple Sequence Alignment Server (R3D-2-MSA) is a new web service that seamlessly links RNA thre

10 vesicular monoamine type 2 studies) with 356 MSA-P patients, 204 PSP patients, 79 CBS patients, and 6

11 umbers of supermarkets among tracts in all 4 MSAs.

12 ng findings on 6193 patients (1911 PSP, 4282 MSA) fulfilled the inclusion criteria.

13 Meanwhile, in vitro studies of recombinant 6-MSA synthases with both nonhydrolyzable and hydrolyzable

14 s, 204 PSP patients, 79 CBS patients, and 62 MSA-C patients were included in the metaanalysis.

15 east 7900 patients (men; >/=65 years), in 92 MSAs.

16 Implantation of a MSA around the gastroesophageal junction has been shown

17 The logarithm of the total probability of a MSA under a stochastic model of sequence evolution along

18 ss, expressed by the mean species abundance (MSA) metric, resulting from three of the shared socio-ec

19 n that nucleation from methanesulfonic acid (MSA) and amines, which is enhanced with added water, can

20 of DMSP, DMSO(2), and methanesulfonic acid (MSA) did not decrease when exposed to excess concentrati

21 tudies have shown that methanesulfonic acid (MSA) reacts with amines and ammonia to form particles, w

22 production of sulfate, methanesulfonic acid (MSA), and methanesulfinic acid (MSIA) during photodegrad

23 Another precursor is methanesulfonic acid (MSA), produced simultaneously with SO2 during the atmosp

24 Methylseleninic acid (MSA) is a metabolite of selenium (Se) in animal cells th

25 e and increase that of methyl sulfonic acid (MSA), which is needed to close the gap between modeled a

26 d control of VBDs require strong and adapted MSAs with the full participation of all relevant sectors

27 ce of water, but NPF is enhanced when adding MSA to OxA-MA with and without water.

28 This narrative systematic review addressed MSAs targeted to MMPs in Myanmar for malaria prevention.

29 show that rat morphine self-administration (MSA), a paradigm that effectively mimics human opiate ad

30 n = 121) evaluating manometric changes after MSA.

31 sed preoperatively and 6 and 12 months after MSA.

32 semblages from the African Middle Stone Age (MSA) and Arabia, and the earliest artefacts from Austral

33 ch as those in the African Middle Stone Age (MSA) were not thought to exist in Europe until the much

34 resistant to microtubule stabilizing agents (MSAs) and in human tumors resistant to Taxol.

35 mber of microtubule (MT)-stabilizing agents (MSAs) have demonstrated or predicted potential as antica

36 sion (D) in mechanical stability aggregates (MSAs), and increased MWD and geometric mean diameter (GM

37 his carrier consists of mouse serum albumin (MSA) covalently coupled to several PDGFbetaR-recognizing

38 to use a single multiple sequence alignment (MSA) as the basis for various types of analysis.

39 e for sensitive multiple sequence alignment (MSA) collection.

40 the query-based multiple sequence alignment (MSA) implied by the pairwise alignments between the quer

41 While multiple sequence alignment (MSA) is a potent tool to detect the phylogenetic signal,

42 structure-based multiple sequence alignment (MSA) of 497 human protein kinase domains excluding atypi

43 ler for protein multiple sequence alignment (MSA) that, as implemented in the program GISMO and appli

44 ning technique, multiple sequence alignment (MSA), distance distribution prediction and domain-based

45 function from Multiple Sequence Alignments (MSA) are emerging as powerful tools in computational bio

46 sualization of multiple sequence alignments (MSAs) and sequence motifs.

47 Multiple Sequence Alignments (MSAs) are a fundamental operation in genome analysis.

48 gh-quality RNA multiple sequence alignments (MSAs) from diverse biological sources.

49 onstruction of multiple sequence alignments (MSAs) is a crucial step in most homology-based sequence

50 formation from multiple sequence alignments (MSAs) is becoming increasingly important.

51 ion matrix) of multiple sequence alignments (MSAs) through deep residual convolutional neural network

52 e databases of multiple sequence alignments (MSAs), Uniboost10, Uniboost20 and Uniboost30, as a resou

53 types of local multiple sequence alignments (MSAs), we numerically computed the total contribution fr

54 rgent sites in multiple sequence alignments (MSAs), which can stem from erroneous inference of homolo

55 gs included in multiple sequence alignments (MSAs).

56 d mutations in multiple sequence alignments (MSAs).

57 bility of deep multiple sequence alignments (MSAs).

58 residues from multiple sequence alignments (MSAs).

59 PMCA was nonreactive in all CON, whereas all MSA samples were positive.

60 gorithm will in almost every case produce an MSA with an optimal set of homologs whose conservation a

61 tio of the number of PrEP patients within an MSA to the number of newly diagnosed individuals with HI

62 ybridization (CGH), microsatellite analysis (MSA), multiplex ligation-dependent probe amplification (

63 At baseline, patients with MSA-P (n=126) and MSA-C (n=49) had much the same symptoms and functional s

64 .2%, g = -0.86, 95% CI = -1.50 to -0.21) and MSA-P (striatum: 31.4%, g = -0.70, 95% CI = -1.21 to -0.

65 related with reduced survival in PD, DLB and MSA.

66 phy in AD, ALS, FTD and PSP (Crus I/II), and MSA and PSP (lobules I-IV), respectively.

67 types: MSA with predominant parkinsonism and MSA with predominant cerebellar ataxia, which generally

68 t distinct alpha-syn strains underlie PD and MSA and offer possible directions for synucleinopathy di

69 he most seed-competent fractions from PD and MSA brains are those that contain Sarkosyl-insoluble alp

70 We conclude that PD and MSA feature alpha-syn conformers with very distinct bioc

71 lpha-syn seeds in brain extracts from PD and MSA patients.

72 The fractions differed between PD and MSA, consistent with the presence of distinct conformers

73 cantly lower in MSA-P and PSP than in PD and MSA-C patients and might therefore be of interest for di

74 cantly lower in MSA-P and PSP than in PD and MSA-C patients and might therefore be of interest for di

75 of PSP patients than in that of both PD and MSA-C patients.

76 of PSP patients than in that of both PD and MSA-C patients.

77 clearly lower in PSP patients than in PD and MSA-P patients and is clearly lower in MSA-P patients th

78 ate HR 1.22; 95% CI 0.83 to 1.80).In PSP and MSA, survival was predicted by early falls (multivariate

79 cantly lower hypothalamic binding in PSP and MSA-P than PD.

80 associated with shorter survival in PSP and MSA.

81 n sea salt sulfate (3-4% OO, 35-40% SI), and MSA (1-2% OO, 11-12% SI).

82 ossible molecular precursors for sulfate and MSA, and we demonstrate that a wide range of relevant cl

83 VD was devised using a multi-stage approach (MSA) with two or three stages, including both non-random

84 (MARC) zones using multisectoral approaches (MSA).

85 The need for multisectoral approaches (MSAs) in prevention and control of vector-borne diseases

86 promote the use of multisectoral approaches (MSAs) in the prevention and control of vector-borne dise

87 e health sector in multisectoral approaches (MSAs) is important for prevention and control of chikung

88 orithm that calculates the first-approximate MSA probability by multiplying total parsimonious contri

89 thin the same metropolitan statistical area (MSA).

90 ) identified metropolitan statistical areas (MSAs) within the US where there is relatively low uptake

91 minergic systems in multiple-system atrophy (MSA) and progressive supranuclear palsy (PSP) than in Pa

92 disease (IPD) from multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), the most

93 Lewy bodies (DLB), multiple system atrophy (MSA) and pure autonomic failure (PAF).

94 y bodies (DLB), and multiple system atrophy (MSA) are characterized by pathological accumulation of a

95 's disease (PD) and multiple system atrophy (MSA) are distinct clinical syndromes characterized by th

96 ration (PSP/CBD) or multiple-system atrophy (MSA) by PET and clinical follow-up were associated with

97 D, and six cases of multiple system atrophy (MSA) for their ability to induce alpha-synuclein aggrega

98 Multiple system atrophy (MSA) is a neurodegenerative disease characterised by gli

99 Multiple system atrophy (MSA) is a progressive neurodegenerative disorder charact

100 Multiple system atrophy (MSA) is a sporadic orphan neurodegenerative disorder.

101 hies, which include multiple system atrophy (MSA), Parkinson's disease, Parkinson's disease with deme

102 al sclerosis (ALS), multiple system atrophy (MSA), progressive supranuclear palsy (MSP)).

103 Multiple-system atrophy (MSA), progressive supranuclear palsy (PSP), and corticob

104 ear palsy (PSP) and multiple system atrophy (MSA), which have similar characteristics in the early st

105 wy bodies (DLB) and multiple system atrophy (MSA).

106 ear palsy (PSP) and multiple system atrophy (MSA).

107 wy bodies (DLB) and multiple system atrophy (MSA).

108 y bodies (DLB), and multiple system atrophy (MSA).

109 d impact of magnetic sphincter augmentation (MSA) on the lower esophageal sphincter (LES).

110 on approved magnetic sphincter augmentation (MSA) with the LINX Reflux Management System (Torax Medic

111 le methods and strategies based on available MSA size and computing resources.

112 We propose a novel, web-based MSA visualization tool called NX4, which can handle geno

113 rfect separation of reactive samples between MSA and Lewy body synucleinopathies.

114 (123)I-FP-CIT SPECT binding to SERT between MSA, PSP, and PD.

115 thresholds for a heatwave episode in Boston MSA based on 16 years of daily observations.

116 We build MSA of highly stable sequences in target LP structures,

117 To characterize MSA errors using these tools, we constructed three sets

118 tingly, we found that a simple combinatorial MSA sampling algorithm will in almost every case produce

119 d the unused potential of optimally composed MSAs for conservation analysis.

120 n investigational setting to further confirm MSA as treatment for GERD.

121 the appropriate columns of the corresponding MSA and returns the contents of the columns, either for

122 el was validated by using synthetic covalent MSA-2 dimers, which were potent agonists.

123 detect the phylogenetic signal, the current MSA implementations are optimized to align the maximum n

124 d is attributed to three factors: the deeper MSA from the metagenome sequence data, improved feature

125 n derived from review of nearly 200 definite MSA cases in the Mayo Clinic Brain Bank.

126 discovery cohort of well-characterized early MSA patients (n = 24) and matched healthy controls (CON,

127 gomers in CSF faithfully differentiate early MSA not only from CON but also from Lewy body synucleino

128 ively enrolled cohort of patients with early MSA (n = 38), Parkinson disease (PD, n = 16), and dement

129 Overall, our results suggest that exogenous MSA inhibited angiogenesis at nutritional Se levels not

130 The advocacy for MSA and necessary capacity building will be integrated i

131 for CGH, 1 study reported survival data for MSA, 3 studies reported survival data for MLPA, 3 studie

132 thm achieved 90% specificity and 85% PPV for MSA and 94% specificity and 94% PPV for PSP.

133 sed individuals with HIV infection, we found MSAs with relatively low uptake of PrEP were concentrate

134 nic sources of OSCs, with contributions from MSA and H2SO4 of a similar order of magnitude.

135 th markedly different reaction kinetics from MSA; aggregation occurred later, but maximum fluorescenc

136 y and 90% specificity in separating PSP from MSA.

137 lutionary couplings that can be derived from MSAs.

138 l ab initio approach of parsing domains from MSAs alone without using known protein structures was a

139 ebellar atrophy were found for AD, ALS, FTD, MSA, and PSP.

140 e effective LP Hamiltonians used to generate MSA are not simple pairwise models due to the competitio

141 First, DeepMSA was utilized to generate MSAs for residue-level contact prediction by six coevolu

142 of them, can clearly visualize where and how MSA errors occurred and help disentangle composite error

143 were to support a landscape analysis of how MSAs have been used in the prevention and control of VBD

144 However, MSA visualizations such as sequence logos and matrix rep

145 l Diseases provides a framework to implement MSAs for prevention and control of VBDs.

146 Based on the improved MSA constructed from the metagenome sequence data, we de

147 In MSA, putaminal susceptibility was increased compared to

148 In MSA, severe dysautonomia and early development of combin

149 n in MSA further we examined ETC activity in MSA and control brain tissue, compared with Parkinson's

150 with increased complex I and IV activity in MSA cerebellar white matter.

151 ng association in PAF, and no association in MSA.

152 It has been shown to be deficient in MSA brain tissue, thus implicating mitochondrial dysfunc

153 the deficit in CoQ10 previously described in MSA and reflects the high regional pathological burden o

154 To investigate mitochondrial dysfunction in MSA further we examined ETC activity in MSA and control

155 tudy highlights mitochondrial dysfunction in MSA pathogenesis, suggests an influence on selective reg

156 hus implicating mitochondrial dysfunction in MSA.

157 scovery cohort, NFL was markedly elevated in MSA patients, with perfect separation from CON.

158 triatal presynaptic dopaminergic function in MSA parkinsonism variant (MSA-P), MSA cerebellar variant

159 T binding to SERT are significantly lower in MSA-P and PSP than in PD and MSA-C patients and might th

160 T binding to SERT are significantly lower in MSA-P and PSP than in PD and MSA-C patients and might th

161 D and MSA-P patients and is clearly lower in MSA-P patients than in MSA-C patients.

162 I = -1.21 to -0.19) and was clearly lower in MSA-P than in MSA-C (striatum: 46.0%, g = 1.46, 95% CI =

163 , binding ratios were significantly lower in MSA-P, PSP, and PD than MSA-C patients.

164 ostural instability in PD and DLB but not in MSA.

165 0.19) and was clearly lower in MSA-P than in MSA-C (striatum: 46.0%, g = 1.46, 95% CI = 0.23 to 2.68)

166 amus were significantly lower in PSP than in MSA-C patients, and we observed significantly lower stri

167 amus were significantly lower in PSP than in MSA-C patients, and we observed significantly lower stri

168 d is clearly lower in MSA-P patients than in MSA-C patients.

169 We also review some controversial topics in MSA.

170 LOCUS T orthologs: FT1 in leaves and FT2 in MSAs.

171 ospitalization in a VA or non-VA hospital in MSAs that contained at least 1 VA and non-VA hospital.

172 neurotoxicity in synucleinopathies including MSA.

173 We demonstrate that incorporating MSA induced uncertainty into bootstrap sampling can sign

174 oach to identifying biologically informative MSAs.

175 ts in the formation of methanesulfonate ion (MSA(-))H3O(+) ion pair.

176 on of metabolic covariance patterns for IPD, MSA, and PSP.

177 ividual scan data, the probabilities of IPD, MSA, and PSP were computed and used to classify each of

178 easy-to-use and scalable analysis for large MSA studies.

179 a probability distribution of fairly likely MSAs, instead of just searching for a single optimum MSA

180 first-approximate probability of each local MSA with its absolute frequency in the MSAs created via

181 al parsimonious contributions from all local MSAs.

182 We estimated a global area-weighted mean MSA of 0.56 for 2015.

183 o close the gap between modeled and measured MSA concentrations.

184 Moreover, MSA effectively inhibited the sprouts of mouse aortic ri

185 sonism [MSA-P], n = 9), cerebellar type MSA (MSA-C, n = 7), PSP (n = 13), and PD (n = 30).

186 sonism [MSA-P], n = 9), cerebellar type MSA (MSA-C, n = 7), PSP (n = 13), and PD (n = 30).

187 Paul Metropolitan Statistical Area (MSP MSA) yield CBLF reductions from -1.9% (from single- to m

188 ombined autonomic and motor features but not MSA phenotype (multivariate HR 1.22; 95% CI 0.83 to 1.80

189 leads to facilitation of the acquisition of MSA in rats, without affecting the extinction process.

190 iles of effective systemic administration of MSA-2.

191 hase DMS oxidation produces equal amounts of MSA and sulfate, a result that has significant implicati

192 ecline proportionally with concentrations of MSA and amines if temperature also decreases, for exampl

193 nt role in clinicopathological correlates of MSA.

194 ostic accuracy and differential diagnosis of MSA as well as candidate biomarkers.

195 , which has been a non-supporting feature of MSA, is considered from both clinical and pathological p

196 , that clinical and pathological features of MSA are broader than previously considered.In this revie

197 Both soluble and insoluble fractions of MSA extracts had robust seeding activity, whereas only t

198 vel mechanistic insight into the function of MSA for regulating angiogenesis and suggest that MSA cou

199 kinsonism; the neuropathological hallmark of MSA is glial cytoplasmic inclusions consisting of filame

200 The cytopathological hallmark of MSA is the accumulation of alpha-synuclein (alpha-syn) a

201 Here we report the identification of MSA-2, an orally available non-nucleotide human STING ag

202 (PLP-SYN) mice, a transgenic mouse model of MSA.

203 The morphology of MSA-seeded inclusions differed from PD-seeded inclusions

204 escribe recent advances in neuropathology of MSA from a review of the literature and from information

205 Cellular potency of MSA-2 increased upon extracellular acidification, which

206 erally more efficient than the production of MSA and MSIA, as well as volatile S-containing compounds

207 xalic acid (OxA) on NPF from the reaction of MSA and methylamine (MA) at 1 atm and 294 K in the prese

208 of particle formation from the reactions of MSA with trimethylamine (TMA), dimethylamine (DMA), meth

209 The daylength sensitivity of MSA development had two phases, floret primordia initiat

210 To study the relative binding affinities of MSAs, tubulin from different sources, with distinct beta

211 atform for the joint explorative analysis of MSAs and phylogenetic trees, employing Sequence Bundles

212 A straightforward conservation analysis of MSAs composed of randomly selected homologs sampled from

213 s, requirements, challenges, and benefits of MSAs has been missing.

214 as also found that appropriate collection of MSAs can further improve the accuracy of final contact-m

215 vance to the possible use of combinations of MSAs to regulate MT activity and improve therapeutic pot

216 tems to assess the performance and impact of MSAs.

217 guidance framework for the implementation of MSAs.

218 ogies, averaging over a very large number of MSAs.

219 dobenzoyl)taxol, alone or in the presence of MSAs.

220 to represent a distribution in the space of MSAs, and allows for existing algorithms to be efficient

221 missioning a series of scientific reviews on MSAs in 5 thematic areas, sharing the key findings of th

222 stead of just searching for a single optimum MSA.

223 th a likely or confirmed diagnosis of PSP or MSA were eligible for inclusion.

224 ic mouse tumor models, subcutaneous and oral MSA-2 regimens were well tolerated and stimulated interf

225 GISMO fills a different niche than other MSA programs, namely identifying and aligning a conserve

226 structures, we estimate the accuracy of our MSA to be 97%.

227 unction in MSA parkinsonism variant (MSA-P), MSA cerebellar variant (MSA-C), PSP, CBS, and PD using c

228 tem atrophy with predominantly parkinsonism [MSA-P], n = 9), cerebellar type MSA (MSA-C, n = 7), PSP

229 tem atrophy with predominantly parkinsonism [MSA-P], n = 9), cerebellar type MSA (MSA-C, n = 7), PSP

230 arkinsonism to another diagnostic group (PD, MSA, PSP, or CBS) were included.

231 SPECT" OR "SPET" and keywords related to PD, MSA, PSP, and CBS.

232 pare atmospheric concentrations of gas phase MSA, H2SO4, and SO2 under current emissions of fossil fu

233 sequences, is more accurate than the popular MSA programs MUSCLE, MAFFT, Clustal-Omega and Kalign.

234 esting pressure (18 pre-MSA vs 23 mm Hg post-MSA; P = 0.0003), residual pressure (4 vs 9 mm Hg; P < 0

235 cts with antifibrotic potential, such as pPB-MSA-Y27632.

236 DGFbeta-receptor, using the drug carrier pPB-MSA.

237 h a targeted construct, by encapsulating pPB-MSA-Y27632 in biodegradable polymeric microspheres, ther

238 using a mouse albumin-based equivalent (pPB-MSA).

239 ted the in vivo antifibrotic efficacy of pPB-MSA-Y27632-loaded microspheres in the Mdr2-/- mouse mode

240 e in the median LES resting pressure (18 pre-MSA vs 23 mm Hg post-MSA; P = 0.0003), residual pressure

241 cerebellar areas implicated for motor (PSP, MSA) or cognitive symptoms (FTD, ALS, PSP) in the diseas

242 considerable neighborhoods of reconstructed MSAs in about 80-99% of the erroneous segments for small

243 urther improve the accuracy of reconstructed MSAs would substantially differ depending on the types o

244 eously reconstructed segments, reconstructed MSAs by each aligner showed complete-likelihood scores n

245 Then, we reconstructed MSAs using MAFFT and Prank as representative state-of-th

246 tween HMSA and (R1)(R2)NH, and the resulting MSA(-)(R1)(R2)NH2(+) complex is bound by one to four int

247 pMSA, a new open-source method for sensitive MSA construction, which has homologous sequences and ali

248 matory cohort, NFL again perfectly separated MSA from CON, and was significantly lower in PD and DLB

249 ools, we constructed three sets of simulated MSAs of selectively neutral mammalian DNA sequences, wit

250 vided into two clinicopathological subtypes: MSA with predominant parkinsonism and MSA with predomina

251 gnificantly lower in MSA-P, PSP, and PD than MSA-C patients.

252 eptor (MOR) is expressed on DG NSCs and that MSA leads to a two-fold elevation of endogenous MOR leve

253 Herein, we demonstrate that MSA inhibited angiogenesis at 2 microM, which falls in t

254 We also found that MSA down-regulated integrin beta3 at the levels of mRNA

255 We found that MSA treatments at 2 microM increased cell adherence, whi

256 Additionally, results showed that MSA inhibited the phosphorylation of AKT, IkappaBalpha,

257 imental and theoretical analyses showed that MSA-2 exists as interconverting monomers and dimers in s

258 for regulating angiogenesis and suggest that MSA could be a potential candidate or adjuvant for anti-

259 The MSA is appropriate for the clinical evaluation of EVD tr

260 The MSA led to a smaller number of cases receiving ineffecti

261 The MSA samples were more potent than those of idiopathic PD

262 Both the MSA and SRCT led to substantially fewer deaths than a co

263 s were built on parameters that describe the MSA, the predicted secondary structure, the predicted so

264 two epidemic scenarios were compared for the MSA, a sequential randomised controlled trial (SRCT) wit

265 seemed due to inadequate exploration of the MSA space.

266 re" here) can serve as an ideal score of the MSA.

267 ers for further growth, their effects on the MSA-amine system are not known.

268 ce exploitation on a comparable scale to the MSA and dated to ~86 to 106 thousand years ago.

269 ng effective treatments correctly, while the MSA was less likely to recommend treatments that were in

270 local MSA with its absolute frequency in the MSAs created via a genuine sequence evolution simulator,

271 earch clusters by keywords and explore their MSAs, taxonomic representation, and annotations.

272 I) consisting of alpha-synuclein; therefore, MSA is included in the category of alpha-synucleinopathi

273 The inhibitory effects elicited by these MSAs on photolabeling were distinct for beta-tubulin fro

274 ctive pairwise Potts Hamiltonians from those MSA.

275 ignificantly lower in PD and DLB compared to MSA.

276 The addition of OxA to MSA-MA mixtures yields a modest NPF enhancement, whereas

277 enhancement, whereas the addition of OxA to MSA-MA-H2O has no effect.

278 s by position-shift maps indicated that true MSAs are in considerable neighborhoods of reconstructed

279 hood scores not lower than those of the true MSAs.

280 rence in each residue's position between two MSAs onto one of them, can clearly visualize where and h

281 arkinsonism [MSA-P], n = 9), cerebellar type MSA (MSA-C, n = 7), PSP (n = 13), and PD (n = 30).

282 arkinsonism [MSA-P], n = 9), cerebellar type MSA (MSA-C, n = 7), PSP (n = 13), and PD (n = 30).

283 We included patients with parkinsonian type MSA (multiple-system atrophy with predominantly parkinso

284 We included patients with parkinsonian type MSA (multiple-system atrophy with predominantly parkinso

285 onfirmed by esophageal pH testing undergoing MSA.

286 Uniboost MSAs of three diversities are built by enriching the Uni

287 sities are built by enriching the Uniclust30 MSAs with local sequence matches from MMseqs2 profile se

288 ism variant (MSA-P), MSA cerebellar variant (MSA-C), PSP, CBS, and PD using combined quantitative dat

289 nergic function in MSA parkinsonism variant (MSA-P), MSA cerebellar variant (MSA-C), PSP, CBS, and PD

290 a lack of studies characterizing PD- versus MSA-derived alpha-syn strains or demonstrating stable pr

291 However, it remains unclear whether MSA exerts its effects on cancer prevention by influenci

292 d 134 patients with PD, 11 with PSP, 10 with MSA and 44 healthy controls.

293 oQ10) biosynthesis, has been associated with MSA.

294 clusions from the brains of individuals with MSA are made of two types of filament, each of which con

295 xtracted from the brains of individuals with MSA differ from those formed in vitro using recombinant

296 ilaments from the brains of individuals with MSA differ from those of individuals with DLB, which sug

297 At baseline, patients with MSA-P (n=126) and MSA-C (n=49) had much the same symptom

298 d 67% of the time to a normal sphincter with MSA.

299 .5 years (range 19.7-71.6) were treated with MSA between March 2013 and August 2015.

300 Mean aggregated within-MSA differences in mortality and readmission rates were

301 In within-MSA comparisons, VA hospitals had lower mortality rates